Superior outcome for splenectomised patients in a population-based study of splenic marginal zone lymphoma in Sweden.

British Journal of Haematology
Andreea SimaRose-Marie Amini

Abstract

Splenic marginal zone lymphoma (SMZL) is a rare low-grade B-cell lymphoma where associations with viral hepatitis and autoimmune and inflammatory diseases (AID) have been indicated. We aimed at assessing the prevalence of viral hepatitis and AID at SMZL diagnosis and outcome by treatment in a Swedish population-based study. A total of 277 SMZL patients registered in the Swedish Lymphoma Register in 2007-2017 were included. A history of viral hepatitis was reported in five (2%) patients and AID prior to SMZL in 72/240 (30%) patients. Treatment was given up front for 207 (75%) patients. Splenectomy with or without systemic treatment was performed in 119 (57%) and was associated with statistically significantly better overall survival [hazard ratio, HR = 0·47 (95% confidence interval, CI: 0·23-0·93), P = 0·03] and progression-free survival (HR = 0·55, 95% CI: 0·35-0·86, P = 0·008) compared to non-splenectomised patients in multivariable analyses. The up-front splenectomised group was younger and generally had a lower Ann Arbor stage, but also more frequently B symptoms and high lactate dehydrogenase than the non-splenectomised group. Viral hepatitis and AID history did not affect SMZL outcome. We report high incidence of AIDs and ...Continue Reading

References

Jul 12, 2002·The New England Journal of Medicine·Olivier HermineXavier Troussard
Nov 26, 2002·Blood·Vito FrancoEmilio Iannitto
Apr 20, 2004·International Journal of Cancer. Journal International Du Cancer·Renato TalaminiSilvia Franceschi
Apr 15, 2009·International Journal of Cancer. Journal International Du Cancer·Lesley A AndersonEric A Engels
Dec 15, 2010·Annals of the Rheumatic Diseases·Martin NeoviusUNKNOWN ARTIS study group
Jul 2, 2014·Scandinavian Journal of Infectious Diseases·Jenny StenkvistKarolin Falconer
Nov 25, 2014·American Journal of Hematology·Jean-Marie MichotUNKNOWN ANRS HC-13 Lympho-C Study Group
Apr 10, 2015·British Journal of Haematology·Katharine H XingDiego Villa
Mar 19, 2016·Blood·Luca ArcainiMarco Paulli
Mar 16, 2017·Best Practice & Research. Clinical Haematology·Larissa Sena Teixeira Mendes, Andrew Wotherspoon
Jun 5, 2017·Revista brasileira de hematologia e hemoterapia·Tayse Silva Dos SantosDanielle Leão Cordeiro de Farias
Feb 18, 2018·Best Practice & Research. Clinical Haematology·Christina KalpadakisTheodoros P Vassilakopoulos
Aug 3, 2018·Blood Cancer Journal·Geffen KleinsternJames R Cerhan
Aug 1, 2019·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Lauren Mk MasonLara Tavoschi
Jan 9, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E ZuccaUNKNOWN ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Feb 14, 2020·Pathology International·Takaharu SuzukiKoichi Ohshima
May 28, 2020·Frontiers in Oncology·Jacob E RobinsonChristine E Cutucache

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.